MT

Muna Therapeutics

www.munatherapeutics.com link_icon

Muna Therapeutics Market Research Report



Company Overview



Name


Muna Therapeutics

Mission of the Company


Muna Therapeutics is focused on discovering and developing therapies that slow or stop devastating neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease.

Founding Information


  • When was the company founded and by whom: No information is available

  • Key people in the company:

  • Rita Balice-Gordon, PhD - Chief Executive Officer

  • Anders Hinsby, PhD - Chief Operating Officer

  • Niels Plath, PhD - Chief Scientific Officer

  • Jakob Busch-Petersen, PhD - Chief Development Officer

  • Pernille Aasholm - Head of People

  • Elizabeth Birch, PhD - Head of Business Development

  • Manuela Polydoro, PhD - Head of Translational Medicine

  • Lars Christian Roenn, PhD - Head of Preclinical Biology

  • Joachim Vilstrup, PhD - Head of Protein Chemistry and Structural Biology

  • Maria Dalby, PhD - Head of Bioinformatics

  • Wei-Ting Chen, PhD - Head of Discovery Biology

  • Heleen Verlinden, PhD - Head of Operations, Leuven and Program Management

  • Peter Flagstad, PhD - Program Head

  • Kim Andersen, PhD - Program Head

  • Donald Nicholson - Independent Chair of Board of Directors


Headquarters


  • Where is the company headquartered: Copenhagen, Denmark and Boston, US


Number of Employees


No information is available

Revenue


No information is available

What is the company known for


Muna Therapeutics is recognized for its groundbreaking work in developing therapies that aim to preserve cognition and other brain functions, enhance resilience to disease pathology, and slow or stop the progression of neurodegenerative diseases.

Products



What products do they offer


Muna Therapeutics offers small molecule drug discovery programs focused on treating neurodegenerative diseases.

High-level description of the product and key features


1. TREM2 Agonism for Alzheimer’s Disease:
  • Description: This program focuses on early-stage Alzheimer’s Disease and aims to activate TREM2, a key signaling molecule in microglial cells.

  • Key Features: Small molecule agonists with high selectivity and potency, capable of enhancing microglial function to clear pathological hallmarks of Alzheimer’s Disease.


2. Kv1.3 Blockade for Parkinson’s Disease and Multiple Sclerosis:
  • Description: This program targets the Kv1.3 potassium channel, known to regulate microglial reactivity and inflammatory responses.

  • Key Features: Small molecules with high selectivity and potency that aim to block Kv1.3, reduce neuroinflammation, and protect neurons from degeneration.


Recent Developments



Recent Grants and Appointments


  • October 11, 2022: Muna Therapeutics was awarded a $4.9M grant from The Michael J. Fox Foundation for Parkinson’s Research. This grant will support the development of disease-modifying therapy for Parkinson’s Disease.

  • November 1, 2021: Dr. Niels Plath was appointed as Chief Scientific Officer.

  • September 13, 2021: Dr. Donald Nicholson was appointed as Independent Chair of the Board of Directors.


New Product Launches


No information is available

New Features Added to Existing Products


No information is available

New Partnerships


No information is available




© 2023 Muna Therapeutics